# Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

> **NCT06918002** · PHASE3 · RECRUITING · sponsor: **Intergroupe Francophone du Myelome** · enrollment: 824 (estimated)

## Conditions studied

- Multiple Myeloma, Newly Diagnosed

## Interventions

- **DRUG:** Elranatamab
- **DRUG:** Lenalidomide (Revlimid®)
- **DRUG:** Daratumumab SC (Darzalex)
- **PROCEDURE:** Autologous Stem Cell Transplantation
- **DRUG:** Bortezomib (Velcade®)
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT06918002
- **Lead sponsor:** Intergroupe Francophone du Myelome
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-09
- **Primary completion:** 2036-05
- **Final completion:** 2036-05
- **Target enrollment:** 824 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06918002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06918002, "Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06918002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*